BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32362156)

  • 1. Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States.
    Su J; Bylsma LC; Jiang X; Morales Arias J; Jain N; Nordyke RJ
    J Med Econ; 2020 Aug; 23(8):902-907. PubMed ID: 32362156
    [No Abstract]   [Full Text] [Related]  

  • 2. Healthcare resource utilization among patients with cold agglutinin disease in Denmark.
    Vágó EK; Nicholson G; Horváth-Puhó E; Hooda N; Fryzek JP; Su J
    Curr Med Res Opin; 2021 Oct; 37(10):1829-1835. PubMed ID: 34308723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An observational analysis of disease burden in patients with cold agglutinin disease: Results from a large US electronic health record database.
    Pham HP; Wilson A; Adeyemi A; Miles G; Kuang K; Carita P; Joly F
    J Manag Care Spec Pharm; 2022 Dec; 28(12):1419-1428. PubMed ID: 36427340
    [No Abstract]   [Full Text] [Related]  

  • 4. Matched cohort study of healthcare resource utilization and costs in young children of mothers with postpartum depression in the United States.
    Moore Simas TA; Huang MY; Packnett ER; Zimmerman NM; Moynihan M; Eldar-Lissai A
    J Med Econ; 2020 Feb; 23(2):174-183. PubMed ID: 31597499
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately vs not adequately controlled disease: a multi-country chart review.
    Chen K; Krasner A; Li N; Xiang CQ; Totev T; Xie J
    J Med Econ; 2019 Nov; 22(11):1141-1152. PubMed ID: 31124721
    [No Abstract]   [Full Text] [Related]  

  • 6. Healthcare resource utilization and costs associated with patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive NSCLC in the United States.
    Samuelsen C; Lim J; Golembesky A; Shrestha S; Wang L; Griebsch I
    J Med Econ; 2020 Jan; 23(1):48-53. PubMed ID: 31314630
    [No Abstract]   [Full Text] [Related]  

  • 7. Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants.
    Watson C; Xu H; Princic N; Sruti I; Barlev A
    J Med Econ; 2020 Oct; 23(10):1159-1167. PubMed ID: 32643493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population.
    Lee S; Xie L; Wang Y; Vaidya N; Baser O
    J Med Econ; 2018 Jun; 21(6):564-570. PubMed ID: 29359606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
    Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
    J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
    [No Abstract]   [Full Text] [Related]  

  • 10. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
    Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
    J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database.
    Bhowmik D; Hines DM; Intorcia M; Wade RL
    J Med Econ; 2018 Jun; 21(6):622-628. PubMed ID: 29571273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
    Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
    J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare resource utilization and expenditures among newly-diagnosed elderly non-valvular atrial fibrillation patients initiating oral anticoagulants.
    Chowdhury R; Franchino-Elder J; Wang L; Yuce H; Wang C; Hartaigh BO
    J Med Econ; 2019 Dec; 22(12):1338-1350. PubMed ID: 31549883
    [No Abstract]   [Full Text] [Related]  

  • 14. Healthcare resource utilization and direct medical costs associated with index and recurrent
    Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
    J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
    [No Abstract]   [Full Text] [Related]  

  • 15. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
    Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
    J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
    [No Abstract]   [Full Text] [Related]  

  • 16. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients.
    Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q
    PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and costs in the 12 months following hospitalization for respiratory syncytial virus or unspecified bronchiolitis among infants.
    Ledbetter J; Brannman L; Wade SW; Gonzales T; Kong AM
    J Med Econ; 2020 Feb; 23(2):139-147. PubMed ID: 31432723
    [No Abstract]   [Full Text] [Related]  

  • 18. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
    Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
    J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
    [No Abstract]   [Full Text] [Related]  

  • 19. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs.
    Manceur AM; Ding Z; Muser E; Obando C; Voelker J; Pilon D; Kinkead F; Lafeuille MH; Lefebvre P
    J Med Econ; 2020 Oct; 23(10):1092-1101. PubMed ID: 32609019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.
    Wang SX; Ganguli AX; Bodhani A; Medema JK; Reichmann WM; Macaulay D
    J Med Econ; 2017 Dec; 20(12):1299-1306. PubMed ID: 28880733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.